News | Artificial Intelligence | January 16, 2017

Artificial Intelligence Will be Used to Improve Lung Cancer Screenings

Third annual Data Science Bowl calls on amateur and career data scientists to help improve cancer screening technology by lowering false-positive rates

January 16, 2017 — Management consulting firm Booz Allen Hamilton  and data analytics company Kaggle recently announced that the third annual Data Science Bowl will inspire data scientists and medical communities around the world to use artificial intelligence to improve lung cancer screening technology. This year’s Data Science Bowl aligns to the call of the Vice President’s “Cancer Moonshot”, announced in January 2016, to unleash the power of data to help end cancer as we know it. The 90-day Data Science Bowl competition will award winners with $1 million in prizes. The funds for the prize purse will be provided by the Laura and John Arnold Foundation.

“Cancer is an intensely personal disease for so many of us: it hits loved ones at home, colleagues at work and friends in our communities. Improving cancer screening and treatment is among the most important responsibilities we have in the next decade,” said Josh Sullivan, Ph.D., senior vice president, Booz Allen Hamilton. “Artificial intelligence and human ingenuity can be powerful in the fight against cancer. Through last year’s Data Science Bowl, hedge fund analysts who had no medical experience created an algorithm that can review heart MRI [magnetic resonance imaging] images on par with trained technicians, helping to better heart disease screening. This year, data scientists — professional and hobbyists alike — can make a difference in the lives of millions of people facing a cancer diagnosis.”

Low-dose computed tomography (CT) scans can reduce lung cancer deaths by 20 percent, as demonstrated in National Cancer Institute (NCI) sponsored screening trials. This reduction would save more lives each year than any cancer-screening test in history. However, there are significant challenges as low-dose CT scans have a high false-positive rate, creating patient anxiety and potentially leading to costly and unnecessary diagnostic work like invasive biopsies that put patients at risk for collapsed lungs and other complications. Reducing the false positive rate is a critical step in making these scans available to more patients.

Using a data set of anonymized high-resolution lung scans provided by the Cancer Imaging Program of the NCI, Data Science Bowl participants will develop artificial intelligence algorithms that accurately determine when lesions in the lungs are cancerous, and thereby dramatically decrease the false positive rate of current low-dose CT technology.

The competition receives additional sponsorship and support from a number of leading health and technology organizations, including the American College of Radiology, Amazon Web Services, NVIDIA and many others.

“The Data Science Bowl is an exciting opportunity for data scientists to work with unique data sets that they wouldn’t have access to unless conducting medical research,” said Anthony Goldbloom, CEO, Kaggle. “This year’s competition has an especially important goal. By reducing the false positive rate of low-dose CT scans, we can not only prevent thousands of inaccurate lung cancer diagnoses, but also save lives through critical early detection of cancer.”

For more information: www.datasciencebowl.com

Related Content

RayStation Replacing Existing Treatment Planning System at Leeds Cancer Centre
News | Treatment Planning | September 24, 2018
RaySearch recently strengthened its position in the U.K. market with a major order for the treatment planning system...
Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
LVivo EF Cardiac Tool Now Available for GE Vscan Extend Handheld Mobile Ultrasound
Technology | Cardiovascular Ultrasound | September 19, 2018
DiA Imaging Analysis Ltd. (DiA), a provider of artificial intelligence (AI)-powered ultrasound analysis tools,...
Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
SimonMed Deploys ClearRead CT Enterprise Wide
News | Computer-Aided Detection Software | September 17, 2018
September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologie
Acuson Sequoia
News | Ultrasound Imaging | September 12, 2018
Siemens Healthineers announced the first global installation of its newest ultrasound system, the...
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Veye Chest version 2
News | Lung Cancer | September 11, 2018
Aidence, an Amsterdam-based medical AI company, announced that Veye Chest version 2, a class IIa medical device, has
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr